Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-01-02 @ 6:17 AM
Study NCT ID:
NCT06832267
Status:
RECRUITING
Last Update Posted:
2025-02-18
First Post:
2025-02-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Sponsor:
Zhejiang Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-02-14
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-02-13
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02-13
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-12
First Submit QC Date:
None
Study First Post Date:
2025-02-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-12
Last Update Post Date:
2025-02-18
Last Update Post Date Type:
ACTUAL